{
  "source": "PA-Med-Nec-Vumerity.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2025 P 2184-7\nProgram Prior Authorization/Medical Necessity\nMedication Vumerity® (diroximel fumarate)*\n*Vumerity is excluded from coverage for the majority of our benefits\nP&T Approval Date 1/2020, 11/2020, 5/2021, 5/2022, 5/2023, 5/2024, 5/2025\nEffective Date 8/1/2025\n1. Background:\nVumerity (diroximel fumarate) is indicated for the treatment of relapsing forms of multiple\nsclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and\nactive secondary progressive disease, in adults.\nCoverage will be provided for members who meet the following criteria.\n2. Coverage Criteriaa:\n1. Authorization\na. Vumerity will be approved based on all of the following criteria:\n(1) Diagnosis of clinically isolated syndrome (CIS) or a relapsing form of multiple\nsclerosis (MS) (e.g., relapsing-remitting MS, secondary progressive MS with\nrelapses)\n-AND-\n(2) Prescribed by or in consultation with a specialist in the treatment of MS (e.g.,\nneurologist)\n-AND-\n(3) Both of the following:\n(a) Submission of medical records documenting the trial and failure (after trial\nof at least 4 weeks), contraindication, or intolerance to at least two of the\nfollowing:\n• glatiramer acetate (e.g., Copaxone®)\n• interferon β-1a (e.g., Avonex®, Rebif®)\n• interferon β-1b (e.g., Betaseron®)\n• peginterferon β-1a (Plegridy®)\n• teriflunomide (Aubagio®)\n• Mayzent® (siponimod)\n• fingolimod (Gilenya®)\n© 2025 UnitedHealthcare Services, Inc.\n1\n• Zeposia® (ozanimod)\n• Kesimpta® (ofatumumab)\n-AND-\n(b) Submission of medical records documenting the trial and failure (after trial\nof at least 4 weeks), contraindication, or intolerance to both of the\nfollowing:\n• Bafiertam® (monomethyl fumarate)\n• dimethyl fumarate (generic Tecfidera®) with trial date that started\nAugust 20, 2020 or later\n-AND-\n(4) Patient is not receiving Vumerity in combination with another disease\nmodifying therapy for multiple sclerosis [e.g., interferon beta prep",
    "th trial date that started\nAugust 20, 2020 or later\n-AND-\n(4) Patient is not receiving Vumerity in combination with another disease\nmodifying therapy for multiple sclerosis [e.g., interferon beta preparations,\nglatiramer acetate, dimethyl fumarate (Tecfidera®), Tysabri® (natalizumab),\nfingolimod (Gilenya®), Ocrevus® (ocrelizumab), Lemtrada® (alemtuzumab),\nMavenclad® (cladribine), teriflunomide (Aubagio®), Bafiertam® (monomethyl\nfumarate), Kesimpta® (ofatumumab), Zeposia® (ozanimod) or Mayzent®\n(siponimod)]\nAuthorization will be issued for 12 months.\na State mandates may apply. Any federal regulatory requirements and the member specific\nbenefit plan coverage may also impact coverage criteria. Other policies and utilization\nmanagement programs may apply.\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-\nauthorization based solely on previous claim/medication history, diagnosis codes (ICD-\n10) and/or claim logic. Use of automated approval and re-approval processes varies by\nprogram and/or therapeutic class.\n• Exclusion: Vumerity is excluded from coverage for the majority of our benefits.\n• Supply limits, notification, and/or Step Therapy may be in place.\n4. References:\n1. Vumerity [package insert]. Cambridge, MA: Biogen Inc.; September 2024.\n© 2025 UnitedHealthcare Services, Inc.\n2\nProgram Prior Authorization/Medical Necessity – Vumerity® (diroximel\nfumarate)\nChange Control\n1/2020 New program\n11/2020 Revised step therapy medications due to changes in preferred\nproducts. Removed continuation of therapy allowance and\nreauthorization section. Updated references.\n5/2021 Updated step through both Bafiertam (monomethyl fumarate) and\ndimethyl fumarate (generic Tecfidera). Added requirement of\nmedical record submission.\n5/2022 Annual review with no change to clinical criteria. Updated references.\n5/2023 Annual review. Removed diagnosis header on coverage criteria.\nChanged dimethyl fumarate (generic Tecfidera) wordin",
    "\n5/2022 Annual review with no change to clinical criteria. Updated references.\n5/2023 Annual review. Removed diagnosis header on coverage criteria.\nChanged dimethyl fumarate (generic Tecfidera) wording. Updated\nreferences.\n5/2024 Annual review. Updated the listing of the brand names of step therapy\nmedications. Updated references.\n5/2025 Annual review with no change to clinical criteria. Updated reference.\n© 2025 UnitedHealthcare Services, Inc.\n3"
  ]
}